@Article{Załuska2008,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="12",
number="8",
year="2008",
title="Capecitabine monotherapy in patients with metastatic breast cancer \– single site experience and literature review",
abstract="Breast cancer (BC) is the most frequently diagnosed malignancy in women. In Poland, in 2005 13,000 new cases and 5,000 deaths due to BC were reported. The 5-year survival rate in metastatic BC (mBC) is 25%. Chemo-therapy, which is based on various combined regimens or single-agent therapies, remains the main modality in the treatment of mBC. It is generally accepted that in case of non-rapidly progressing or non life-threatening mBC therapy should be based on single-agent strategies. Single-agent chemotherapy in comparison to polychemotherapy is less toxic but still demonstrates a significant anti-tumour activity.  One of the popular drugs commonly used for monotherapy of mBC is capecitabine, a precursor of 5-fluorouracil.  In the following article we present our experience with single-agent capecitabine in 82 mBC patients treated in the Department of Chemotherapy at the Great Poland Cancer Centre in Poznan, Poland. The objective response rate was 12%. Capecitabine was well tolerated and relatively rare adverse events >G2 were manageable by symptomatic treatment and dose reduction. In general, the clinical efficacy of capecitabine as well as the overall and progression-free survival times observed in our group of mBC patients were similar to those reported in the literature.",
author="Załuska, Joanna
and Prochowska, Ewa
and Karczewska-Dzionk, Aldona
and Załuski, Jerzy
and Wysocki, Piotr J.",
pages="384--387",
url="https://www.termedia.pl/Capecitabine-monotherapy-in-patients-with-metastatic-breast-cancer-8211-single-site-experience-and-literature-review,3,11488,1,1.html"
}